equityhold

GEHC

Current recommendation: Hold. Our primary priced pathway is optional exposure to early neurotech sensory-interface research (ultrasound-driven ‘ghost smells’) and downstream demand for automated gait analytics and biomechanics-derived metrics. These links are speculative and have low confidence.

Opportunity
14 / 100
Current score
0.18
Thesis calls
3
Active ticker theses
1

Recent proof-backed thesis calls

3 published recommendations. Topics: automated gait-analytics and biomechanics from cheaper kinematics inputs; early-stage ultrasound neurotech claiming induced ‘ghost smells’; and general themes around AI adoption in healthcare, data infrastructure, and cybersecurity. The research slate contains mixed verification; several items are high-uncertainty.

arXiv cs.LGrsswrong

Scientific paper proposes a unified benchmark (60 healthy subjects, 3 cadences) to predict hip muscle forces and joint moments directly from gait kinematics using sequence models; Transformer performed best and showed only moderate zero-shot generalization to a small external pathological cohort (9 ONFH patients). Investable implication is not the specific model, but acceleration/automation of gait analytics and biomechanics-derived metrics from cheaper kinematics inputs (wearables/markerless ca

Mentioned: Jun 1, 2026, 12:00 AM EDTConviction: 24 / 100Return: -4.13%
Source: Gait2Hip-60: A Unified Deep Learning Benchmark for Predicting Hip Muscle Forces and Joint Moments from Multi-Cadence Gait Kinematics
yush_gxwrong

A researcher claims they can induce distinct “ghost smells” (e.g., campfire, garbage truck) by targeting the brain with ultrasound—described as rapid to reproduce and (to their knowledge) novel even in animals. This is early-stage neurotech/sensory-interface research with unclear commercialization timeline and no direct public-company linkage yet.

Mentioned: Jun 17, 2026, 11:04 PM EDTConviction: 18 / 100Return: -5.76%
Source: Pinned Yush @yush_g Nov 21, 2025 We made fake smells that don't exist. Creating ghost smells with ultrasound only too...
Stanford Onlineyoutubewrong

Only a title/body were provided; no transcript, link, speaker names, or concrete technical claims to verify. From the topic (“AI in healthcare,” “open evidence,” “cyber risks”), the most plausible tradable implications are: (1) increased adoption of AI/LLMs in clinical workflow and imaging, (2) stronger demand for healthcare data infrastructure/interop tooling, and (3) heightened healthcare cybersecurity spend due to AI-enabled attack surface and regulatory scrutiny. All conclusions are high-unc

Mentioned: Jun 15, 2026, 7:06 PM EDTConviction: 36 / 100Observed price: $64.76 on 2026-06-15Return: -9.98%
Source: AI in Healthcare Series: Inside the Rise of AI in Healthcare, Open Evidence and Cyber Risks

Current stance

Hold. We see optional upside from neurotech adjacency (XR + ultrasound) and from automation of gait analytics, but commercialization paths and timelines are unclear. Confidence in the neurotech linkage is low (~0.18).

Recommendationhold
Authors3
Active ticker theses1
Latest pricen/a
Why now
  • beneficiary via Neurotech sensory-interface optionality lift (XR + ultrasound adjacency) from https://x.com/yush_g (confidence 0.18)

Active and historical ticker theses

One active play: a speculative proxy exposure to neurotech sensory-interface optionality driven by ultrasound research and potential XR adjacency. This is an indirect hardware/workflow proxy; translation to GE HealthCare revenue is uncertain.

Unlock full asset monitoring

Monitor early neurotech experiments and gait-analytics automation research for clearer commercialization signals. Revisit stance if firm product partnerships, clinical validation, or direct revenue linkage to GE HealthCare emerge.